Missing topics at SABCS

Article

The first slide from every presenter at the San Antonio Breast Cancer Symposium indicates whether they have any conflict of interest, which translated into English means whether they are getting paid by a pharmaceutical company or anyone else for anything.Last night at the symptom management educational session, which was packed, the speaker's slide said something to the effect that her topic, lymphedema and weight lifting, did not involve a drug and therefore was of no interest to anyone, so she had no conflict of interest. In other words, there would be no profit involved in what she did, except maybe for a few scattered personal trainers and the gyms where they work.I think I might be getting jaded around the edges. I look at the presentations here and see lots of really complicated topics involving the use of drugs in every conceivable way. But in the midst of all these presentations, where are the researchers who are looking at prevention and the mechanisms that make a cell go haywire in the first place? Where are the studies on the issues that make it possible to live with, through and in spite of breast cancer? These are issues such as depression, pain, sexuality, fatigue and fear. Barbara Anderson's work showed clearly that stress reduction reduced recurrence by 20 percent. If that was a drug, it would be international headlines.I don't want to malign research because I know it's critical, but can we make room for some of the other issues that are so critical to women living through breast cancer? Yesterday in Project LEAD, the opening speaker used a statistic to show how far we have come by noting that there were around 12,300 papers on breast cancer published in 2009 compared to more than 24,000 in 2010. I thought that sounded amazing until the next speaker from the National Breast Cancer Coalition asked whether that was a positive or a negative. Are we rewarding the right thing? Should papers and patents (read money) be the goal?As a former academic, I know firsthand the importance placed on publishing. It is the standard by which teachers are measured. The same is true for researchers. They get funds, their institutions get publicity, and women, sometimes, get the results.Let's celebrate those researchers and make room for studies on quality of life and survivorship.

Related Videos
For patients with cancer, the ongoing chemotherapy shortage may cause some anxiety as they wonder how they will receive their drugs. However, measuring drugs “down to the minutiae of the milligrams” helped patients receive the drugs they needed, said Alison Tray. Tray is an advanced oncology certified nurse practitioner and current vice president of ambulatory operations at Rutgers Cancer Institute in New Jersey.  If patients are concerned about getting their cancer drugs, Tray noted that having “an open conversation” between patients and providers is key.  “As a provider and a nurse myself, having that conversation, that reassurance and sharing the information is a two-way conversation,” she said. “So just knowing that we're taking care of you, we're going to make sure that you receive the care that you need is the key takeaway.” In June 2023, many patients were unable to receive certain chemotherapy drugs, such as carboplatin and cisplatin because of an ongoing shortage. By October 2023, experts saw an improvement, although the “ongoing crisis” remained.  READ MORE: Patients With Lung Cancer Face Unmet Needs During Drug Shortages “We’re really proud of the work that we could do and achieve that through a critical drug shortage,” Tray said. “None of our patients missed a dose of chemotherapy and we were able to provide that for them.” Tray sat down with CURE® during the 49th Annual Oncology Nursing Society Annual Congress to discuss the ongoing chemo shortage and how patients and care teams approached these challenges. Transcript: Particularly at Hartford HealthCare, when we established this infrastructure, our goal was to make sure that every patient would get the treatment that they need and require, utilizing the data that we have from ASCO guidelines to ensure that we're getting the optimal high-quality standard of care in a timely fashion that we didn't have to delay therapies. So, we were able to do that by going down to the minutiae of the milligrams on hand, particularly when we had a lot of critical drug shortages. So it was really creating that process to really ensure that every patient would get the treatment that they needed. For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.
Yuliya P.L Linhares, MD, an expert on CLL
Yuliya P.L Linhares, MD, and Josie Montegaard, MSN, AGPCNP-BC, experts on CLL
Image of a man with a beard.
Image of a man with gray facial hair and a navy blue suit with a light orange tie.
Image of a woman with black hair.